The subject technology is directed to a CO.sub.2-based chromatography system and method for rapid determination of the levels and/or the presence or absence of steroids or steroid derivatives in a sample.

The invention relates to a method for separation of biopolymer molecules, particularly biopolymer molecules from the group consisting of mono- a multi-phosphorylated peptides, recombinant peptides/proteins with a polyhistidine tag (His-tag) or with another chemically similar biospecific tag, cysteine-containing peptides/proteins and nucleic acids, in which a biopolymer molecule is bound in a binding solution by a specific binding to a carrier, which contains a core with dimensions in nano- and/or submicro- and/or microscale, which is composed of oxide of at least one transition metal and/or silicon oxide, on whose surface is deposited at least one continuous or non-continuous layer and/or nanoparticles of magnetic metal oxide and/or such nanoparticles are deposited in its inner structure, and subsequently undesirable and non-specifically bound components are washed off at least once from the carrier-bound bio-molecules by a washing solution, whereupon biopolymer molecules are eluted from it by changing pH and/or by using an elution solution. The invention also relates to a carrier for application of this method.

There are only two ways to increase the amount of sample that can be purified by preparative reversed phase high performance liquid chromatography (Prep-RP-HPLC) in a single run: (1) The traditional approach is to use a bigger column (greater amount of stationary phase); and (2) Use displacement chromatography which uses the stationary phase more effectively. This invention describes a unique Prep-RP-HPLC technique that uses a C-18/C-8 derivatized silica coated with a hydrophobic quaternary ammonium salt or quaternary phosphonium salt to result in 7 to 12 fold increase in sample loading (of the crude mixture of organic compounds including synthetic crude peptides) in contrast to the conventional Prep-RP-HPLC technique. This increase in sample loading capacity and output is due to the additional surrogate stationary phase characteristic of the C-18/C8 bound quaternary salt. The quaternary surfactant is bound to the C-18/C-8 chains and silanols of the stationary phase.

Provided herein are methods of separating host cell lipases from a production protein in chromatographic processes and methods of improving polysorbate-80 stability in a production protein formulation by separating host cell lipases from the production protein using chromatographic processes. Also provided are pharmaceutical compositions comprising less than 1 ppm of a host cell lipase.

Provided is a separatome-based recombinant peptide, polypeptide, and protein expression and purification platform based on the juxtaposition of the binding properties of host cell genomic peptides, polypeptides, and proteins with the characteristics and location of the corresponding genes on the host cell chromosome, such as that of E. coli, yeast, Bacillus subtilis or other prokaryotes, insect cells, mammalian cells, etc. The separatome-based protein expression and purification platform quantitatively describes and identifies priority deletions, modifications, or inhibitions of certain gene products to increase chromatographic separation efficiency, defined as an increase in column capacity, column selectivity, or both. Moreover, the separatome-based protein expression and purification platform provides a computerized knowledge tool that, given separatome data and a target recombinant peptide, polypeptide, or protein, intuitively suggests strategies leading to efficient product purification. The separatome-based protein expression and purification platform is an efficient bioseparation system that intertwines host cell expression systems and chromatography.

A method for concentrating and crystallizing fermentable carboxylic acids, salts, and mixtures thereof may involve the use of carboxylic acids that have a defined temperature dependence of the solubility and of the osmotic pressure. The carboxylic acids may be concentrated by a membrane method and subsequently crystallized out by a cooling crystallization and isolated. In some examples, the membrane method may involve nanofiltration, reverse osmosis, and/or membrane distillation for separation into a concentrate and a permeate. Similarly, an apparatus for implementing such methods may include a nanofiltration, reverse osmosis, and/or membrane distillation unit for concentrating the carboxylic acid, and at least one cooling crystallization unit for crystallizing the carboxylic acid.”

Provided herein are methods relating to the purification of a polypeptide comprising an Fc region (e.g., an antibody) via protein A chromatography; methods relating to the use of a wash solution comprising a benzoate salt and/or benzyl alcohol during protein A chromatography; and methods of adjusting a harvest using sodium benzoate prior to protein A chromatography.

Disclosed is a method of measuring tacrolimus levels in a subject. In exemplary embodiments, the method comprises the steps of: collecting oral fluid from the subject; homogenizing the oral fluid; combining the homogenized oral fluid with a precipitating solvent; separating oral fluid components on a liquid chromatography column by gradient elution with a mixture of a solvent A and a solvent B, wherein the solvent A is about 2 mM ammonium acetate/0.1% (v/v) formic acid in water and solvent B is about 2 mM ammonium acetate/0.1% (v/v) formic acid in MeOH and wherein the amount of solvent B is increased from about 50% (v/v) to about 98% (v/v); and determining amount of tacrolimus in the oral fluid by mass spectrometry.

The present invention provides a chromatographic separation process for recovering a polyunsaturated fatty acid (PUFA) product from a feed mixture, which process comprises passing the feed mixture through one or more chromatographic columns containing, as eluent, an aqueous organic solvent, wherein the temperature of at least one of the chromatographic columns through which the feed mixture is passed is greater than room temperature.

The present invention relates to a novel monascuspurpurone compound of formula (I): ##STR00001##
or a pharmaceutically acceptable derivative thereof as described in the specification, the process for preparation of the same, and the composition comprising the same. The uses of a monascuspurpurone compound for promoting adipocyte differentiation, for increasing the activity of PPARγ and/or C/EBPα, for lowering blood glucose, for preventing and/or treating a disease or disorder related to insulin resistance, and for preventing and/or treating metabolic syndrome or its complications are also provided.